- Athanasou NA, Bansal M, Forsyth R et al. Giant cell tumour of bone. In Fletcher CDM, Bridge JA Hogendoorn PCW Mertens F (Eds): “WHO Classification of Tumours of Soft Tissue and Bone.” Lyon: International Agency for Research on Cancer (IARC), 2013: 321–4.
- Balke M, Streitbuerger A, Budny T et al. Treatment and outcome of giant cell tumors of the pelvis. Acta Orthop 2009; 80(5): 590–6.
- Balke M, Henrichs MP, Gosgheger G et al. Giant cell tumors of the axial skeleton. Sarcoma 2012; 2012: 410973.
- Becker WT, Dohle J, Bernd L et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 2008; 90(5): 1060–7.
- Branstetter DG, Nelson SD, Manivel J C et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012; 18: 4415–24.
- Chawla S, Henshaw R, Seeger L et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013; 14: 901–8.
- van der Heijden L, van de Sande M AJ, Dijkstra P DS. Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant cell tumor of the long bones – A retrospective study of 93 patients. Acta Orthop 2012; 83(4): 401–5.
- Kivioja AH, Blomqvist C, Hietaniemi K et al. Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 2008; 79(1): 86–93.
- Klenke FM, Wenger DE, Inwards C Y et al. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 2011; 469(2): 591–9.
- Kostenuik PJ, Nguyen HQ, McCabe J et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009; 24(2): 182–95.
- Leggon RE, Zlotecki R, Reith J et al. Giant cell tumor of the pelvis and sacrum: 17 cases and analysis of the literature. Clin Orthop Relat Res 2004; (423): 196–207.
- Morgan T, Atkins GJ, Trivett M K et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 2005; 167: 117.
- Roux S, Amazit L, Meduri G et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol 2002; 117: 210–6.
- Thomas DM, Henshaw R, Skubitz K M et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010; 11(3): 275–80.
- Choose new content alerts to be informed about new research of interest to you
- Easy remote access to your institution's subscriptions on any device, from any location
- Save your searches and schedule alerts to send you new results
- Export your search results into a .csv file to support your research